Pancreatic Cancer Research

ResearcherSoochow UniversityNo recent work listed

Dechun Li

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5101671533. Sources: OpenAlex.

Their work

Papers
20 (first author 2, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
38
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 2 papers · 2014: 3 papers · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 3 papers · 2020: none · 2021: 2 papers · 2022: 2 papers

Papers 20

  1. RhoGDI2 induced malignant phenotypes of pancreatic cancer cells via regulating Snail expression. Co-author DOI 10.1007/s13258-022-01217-0↗
  2. B7H6 Serves as a Negative Prognostic Marker and an Immune Modulator in Human Pancreatic Cancer. Last author DOI 10.3389/fonc.2022.814312↗
  3. Huaier increases the antitumor effect of gemcitabine on pancreatic cancer in vitro and in vivo. Co-author DOI 10.21037/tcr-20-2627↗
  4. Signature of gene aberrant alternative splicing events in pancreatic adenocarcinoma prognosis. Co-author DOI 10.7150/jca.48661↗
  5. A Panel of Three Biomarkers Identified by iTRAQ for the Early Diagnosis of Pancreatic Cancer. Co-author DOI 10.1002/prca.201800195↗
  6. DcR3 promotes proliferation and invasion of pancreatic cancer via a DcR3/STAT1/IRF1 feedback loop. Co-author PMID 31911850↗
  7. miR-557 inhibits the proliferation and invasion of pancreatic cancer cells by targeting EGFR. Last author PMID 31933947↗
  8. HIF-2α promotes the formation of vasculogenic mimicry in pancreatic cancer by regulating the binding of Twist1 to the VE-cadherin promoter. Co-author DOI 10.18632/oncotarget.17999↗
  9. Methylation of BNIP3 in pancreatic cancer inhibits the induction of mitochondrial-mediated tumor cell apoptosis. Co-author DOI 10.18632/oncotarget.18736↗
  10. HIF-2α promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer. Co-author DOI 10.1186/s13046-016-0298-y↗
  11. Decoy receptor 3 suppresses FasL-induced apoptosis via ERK1/2 activation in pancreatic cancer cells. First author DOI 10.1016/j.bbrc.2015.06.074↗
  12. MiR-335 functions as a tumor suppressor in pancreatic cancer by targeting OCT4. Co-author DOI 10.1007/s13277-014-2092-9↗
  13. The coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer. Co-author DOI 10.2147/ott.s66809↗
  14. Effects of miR-16 plus CA19-9 detections on pancreatic cancer diagnostic performance. Last author DOI 10.7754/clin.lab.2013.121210↗
  15. Expression levels of microRNA-375 in pancreatic cancer. Last author DOI 10.3892/br.2013.88↗
  16. B7-H3 overexpression in pancreatic cancer promotes tumor progression. First author DOI 10.3892/ijmm.2012.1212↗
  17. MicroRNA-375 is downregulated in pancreatic cancer and inhibits cell proliferation in vitro. Co-author DOI 10.3727/096504013x13589503482734↗
  18. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene … Co-author DOI 10.3892/or.2011.1602↗
  19. Expression of the co-signaling molecules CD40-CD40L and their growth inhibitory effect on pancreatic cancer in vitro. Co-author DOI 10.3892/or.2012.1790↗
  20. Distribution and clinical significance of Th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients. Last author DOI 10.3390/ijms12117424↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jian Zhou · 11 shared papers, 2012–2022 · strength 0.89
  2. Zixiang Zhang · 5 shared papers, 2013–2022 · strength 0.54
  3. Dongming Zhu · 5 shared papers, 2015–2022 · strength 0.52
  4. Yi Zhang · 5 shared papers, 2015–2022 · strength 0.39
  5. Jun Yao · 3 shared papers, 2019–2022 · strength 0.36
  6. Jian Yang · 4 shared papers, 2016–2022 · strength 0.34
  7. Dongming Zhu · 6 shared papers, 2012–2017 · strength 0.32
  8. Yuchen Tang · 2 shared papers, 2021–2022 · strength 0.26
  9. Bin Yi · 2 shared papers, 2021–2022 · strength 0.26
  10. Zixiang Zhang · 4 shared papers, 2012–2019 · strength 0.24
  11. Yijun Wei · 2 shared papers, 2019–2021 · strength 0.22
  12. Songbing He · 3 shared papers, 2011–2022 · strength 0.21
  13. Jian Yang · 2 shared papers, 2019 · strength 0.19
  14. Shiduo Song · 4 shared papers, 2012–2015 · strength 0.16
  15. Xin Zhao · 1 shared paper, 2021 · strength 0.15
  16. Dongbao Li · 1 shared paper, 2021 · strength 0.15
  17. Tao Chen · 1 shared paper, 2021 · strength 0.15
  18. Xin Zhao · 2 shared papers, 2013–2022 · strength 0.14
  19. Qiuhua Liu · 1 shared paper, 2022 · strength 0.13
  20. Yujie Huang · 1 shared paper, 2022 · strength 0.13
  21. Ye Li · 2 shared papers, 2016–2017 · strength 0.13
  22. Xiao‐Yang Wu · 1 shared paper, 2019 · strength 0.12
  23. Yong Yang · 1 shared paper, 2019 · strength 0.12
  24. Ling Gao · 2 shared papers, 2014 · strength 0.12
  25. Hua Zhao · 3 shared papers, 2013–2014 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.